

2004-03-25

Notice to attend the Annual General Meeting in VITROLIFE AB (publ)

The shareholders of Vitrolife AB (publ) are hereby invited to the annual general meeting on 23rd April 2004, at 5 pm, at SEB Göteborg, 4th floor, Östra Hamngatan 24, Göteborg.

Notice of Attendance

Shareholders who wish to attend the annual general meeting must

-be registered in the shareholders' register kept by VPC AB (the Swedish Securities Register) on Tuesday 13th April 2004 and

-give notice of attendance to the Company no later than on Friday 16th April at 12 am, by mail to Vitrolife AB, Faktorvägen 13, 434 37 Kungsbacka, or by fax to +46 (0) 31 721 80 99, at the which the number of assistants shall be stated.

When giving notice of attendance, please state name, personal identity number (date of birth) or company registration number, address and telephone number. If the shareholder intends to be represented by a representative, complete documents showing the due authorisation of the representative such as certificate of registration and power of attorney shall be attached to the notice of attendance.

Shareholders who have registered their shares by a bank, a brokerage firm or another nominee must, in order to be entitled to attend the general meeting, temporarily register its shares in their own name. Such registration must be effectuated on Tuesday 13th April 2004, which means that the shareholder in due time before such date must notify its nominee.

Proposed agenda

1. Opening of the meeting.
2. Election of chairman at the meeting.
3. Preparation and approval of voting list.
4. Approval of the agenda.
5. Election of one or two members to check the minutes.
6. Resolution as to whether the meeting has been duly convened.
7. Presentation of the Annual Report and the Auditor's Report as well as the Group Annual Report and the Group Auditor's Report
8. Statement by the CEO.
9. Resolution as to
 - a) the adoption of the Profit and Loss Statement and the Balance Sheet as well as the Group Profit and Loss Statement and the Group Balance Sheet,
 - b) the allocation of the Company's loss in accordance with the adopted Balance Sheet,
 - c) the discharge from liability for the members of the Board of Directors and the CEO.
10. Resolution as to the number of members and deputy members of the Board of Directors.
11. Resolution as to the number of auditors.
12. Resolution as to the remuneration to the Board of Directors and the auditors.
13. Election of the members of the Board of Directors.
14. Obligatory items for the annual general meeting according to the Swedish Companies' Act or the article of association.
15. The closing of the meeting.

PRESS RELEASE

The Board of Directors' propositions

Dividends (item 9 b)

The Board proposes that no dividends are paid out for the financial year 2003.

Other items

Propositions for election of members to the Board of Directors, remunerations etc will be announced later on.

Documents

Accounts and the auditor's report will be kept available to the shareholders at the Company during two weeks before the Annual General Meeting of shareholders and will be sent free of charge by the Company to shareholders on their request. The documents will also be available on the home page of the Company.

www.vitrolife.com.

Gothenburg in March 2004

VITROLIFE AB (publ)

The Board of Directors



For further information, please contact;

CEO: Dr. Magnus Nilsson

Tel: +46 31 721 80 00

Mobile +46 708 22 80 61

mnilsson@vitrolife.com

Acting CFO and IR agent: Anders Sävfall

Tel: +46 31 721 80 00

mfischer@vitrolife.com

Vitrolife is a global biomedical corporation that works with products for cell and tissue technology. The Vitrolife group consists of the parent company, Vitrolife AB (Publ) and two wholly owned subsidiaries: Vitrolife Sweden AB (Gothenburg, Sweden), Vitrolife Inc. (Denver, Colorado). The group's operations focused on three geographic areas.

- Europe/Middle East
- The Americas
- Rest of the World

Vitrolife's business concept is to develop, produce and sell advanced products and systems for the preparation, cultivation, preservation and support of cells, tissues and organs.

PRESS RELEASE